56.3 F
New York
Tuesday, May 17, 2022

Silence Therapeutics [NASDAQ: SLN] Names Craig Tooman As CFO

Must read

Silence Therapeutics [NASDAQ: SLN] reported that the company has named Craig Tooman as the CFO and as well as a member of the executive leadership team. Craig has more than 25 years of experience in the pharmaceutical industry with a successful career.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Mr. Tooman has about 15 years of experience as the Chief Financial Officer of a public company. He formerly worked as a chief financial officer and chief operating officer at Vyome therapeutics.  Before working at Vyome he was the CEO and CFO at Aratana Therapeutics. At Aratana he successfully managed the merger of the company with Elanco.

He also served in key positions at Enzo pharmaceutical, Genzyme corporation, Pharmacia, and Upjohn. Currently, Craig Tooman is serving on the Supervisory Board and Audit committee of CureVac. It is expected that Craig will bring all of this experience to Silence as the new CFO.

More articles

Latest article